⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8962490 | 1.00 | — | — | |
| SCHEMBL8962505 | 0.81 | — | — | |
| SCHEMBL8962482 | 0.81 | — | — | |
| SCHEMBL8962527 | 0.81 | — | — | |
| SCHEMBL8962767 | 0.81 | — | — | |
| SCHEMBL8962555 | 0.81 | — | — | |
| SCHEMBL8962355 | 0.81 | — | — | |
| SCHEMBL8962502 | 0.81 | SOAT1 (0.54) | — | |
| SCHEMBL9844180 | 0.80 | SMN1; SMN2 (0.58) | — | |
| SCHEMBL8962687 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1996019446-A1 | β-CARBOXY SULFONAMIDE ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1996-06-27 | — | — | WO | claimed |
| US-5491170-A | TREATMENT OF HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1996-02-13 | — | — | US | claimed |
| WO-1996019446-A1 | β-CARBOXY SULFONAMIDE ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1996-06-27 | — | — | WO | disclosed |
| US-5491170-A | TREATMENT OF HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1996-02-13 | — | — | US | disclosed |